Physician profile
Charles E Odowd
NPI 1508937467
$1,947.42
in general payments reported to CMS, 2019-2025
28 companies · $52.93 in 2025
The $52.93 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $208 · 2021: $446 · 2022: $262 · 2023: $498 · 2024: $259 · 2025: $52.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $810.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $495.58 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $197.12 | 2019-2024 | |
| Novo Nordisk INC | $170.35 | 2020-2025 | |
| Exact Sciences Corporation | $168.14 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $127.26 | 2021-2024 | |
| Boston Scientific Corporation | $103.80 | 2021 | |
| Janssen Pharmaceuticals, INC | $87.94 | 2019-2022 | |
| Eisai INC. | $84.19 | 2020-2021 | |
| Almatica Pharma LLC | $47.52 | 2024 | Loreev Xr |
| Arbor Pharmaceuticals, INC. | $40.29 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $36.93 | 2019 | |
| Azurity Pharmaceuticals, INC. | $36.51 | 2023 | Horizant, Adthyza |
| Idorsia Pharmaceuticals US INC | $34.58 | 2023 | Quviviq |
| Amarin Pharma, INC. | $34.02 | 2019 | |
| Adlon Therapeutics L.P. | $30.89 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kvk-Tech, INC. | $26.31 | 2024 | |
| Becton, Dickinson and Company | $24.04 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.87 | 2022 | |
| Lilly USA, LLC | $23.20 | 2024 | Mounjaro, Zepbound |
| Lundbeck LLC | $23.14 | 2024 | Rexulti |
| Vbi Vaccine (Delaware) INC. | $18.83 | 2023 | Prehevbrio |
| Allergan, INC. | $17.40 | 2020 | |
| Astellas Pharma US INC | $16.85 | 2021 | |
| Esperion Therapeutics, INC. | $16.18 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.97 | 2021 | |
| Amgen INC. | $15.94 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.58 | 2025 | Breztri |
| Antares Pharma, INC. | $14.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Odowd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.